What is the recommendation for the use of MRAs in Chronic Heart Failure?
MRAs should be offered to all people with HFREF, as the evidence indicated a beneficial effect across the disease severity spectrum and is likely to remain cost effective. The committee considered whether MRAs should be offered to all people with HFREF who remain symptomatic on after the optimisation of beta- blocker and ACEi dose titration. Furthermore, taking the technology appraisals into consideration, sacubitril valsartan and ivabradine recommendations were added as possible specialist treatments.